Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Yunan Nie"'
Autor:
Tejas Patil, MD, Alyse Staley, MS, Yunan Nie, MD, Mandy Sakamoto, MD, Margaret Stalker, MD, James M. Jurica, MD, MBA, Kenna Koehler, BA, Amanda Cass, PharmD, Halle Kuykendall, BA, Emily Schmitt, MS, Emma Filar, BA, Evelina Reventaite, MS, Kurt D. Davies, PhD, Hala Nijmeh, PhD, Mary Haag, PhD, Benjamin A. Yoder, PharmD, Paul A. Bunn, MD, Erin L. Schenk, MD, PhD, Dara L. Aisner, MD, PhD, Wade T. Iams, MD, Melina E. Marmarelis, MD, D. Ross Camidge, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 2, Pp 100637- (2024)
Introduction: Acquired MET gene amplification, MET exon 14 skip mutations, or MET fusions can emerge as resistance mechanisms to tyrosine kinase inhibitors (TKIs) in patients with lung cancer. The efficacy and safety of combining MET TKIs (such as cr
Externí odkaz:
https://doaj.org/article/63d7bcf67c604305b7273bb565a9b37b
Publikováno v:
Case Reports in Oncology, Vol 15, Iss 1, Pp 277-284 (2022)
Splenic rupture can be categorized into two groups: traumatic and atraumatic. Traumatic rupture is frequently associated with blunt abdominal trauma, while atraumatic splenic rupture (ASR) is more uncommon and has been associated with both benign and
Externí odkaz:
https://doaj.org/article/1550be4639a5410fb87f6ebdeda62c76
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
Pemetrexed (used as a platinum doublet or as a maintenance regimen) is an established therapy for patients with advanced non-squamous non-small-cell lung cancer (NSCLC). In addition, certain gene rearrangements (e.g., ALK, ROS1, RET) appear to especi
Externí odkaz:
https://doaj.org/article/587e53c2c34a47079facfc26c57b9961
Autor:
Jessica J. Lin, Yunan Nie, Alexia Iasonos, Andrew J. Plodkowski, Maria E. Arcila, Debra A. Goldman, Jaime L. Schneider, Viola W. Zhu, Sai-Hong Ignatius Ou, Natasha Rekhtman, Alexander Drilon, Subba R. Digumarthy, Tejas Patil, Jamie E. Chaft, Christina Falcon, Andrew Do, Noura J. Choudhury, Soo-Ryum Yang
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 7, Pp 100187-(2021)
Introduction: ROS1 fusions are oncogenic drivers in 1% to 3% of NSCLCs. The activity of immune checkpoint inhibitor (ICI) monotherapy or in combination with chemotherapy (chemotherapy with ICI [chemo-ICI]) in these tumors and their immunophenotype ha
Autor:
Noura J, Choudhury, Jaime L, Schneider, Tejas, Patil, Viola W, Zhu, Debra A, Goldman, Soo-Ryum, Yang, Christina J, Falcon, Andrew, Do, Yunan, Nie, Andrew J, Plodkowski, Jamie E, Chaft, Subba R, Digumarthy, Natasha, Rekhtman, Maria E, Arcila, Alexia, Iasonos, Sai-Hong I, Ou, Jessica J, Lin, Alexander, Drilon
Publikováno v:
JTO Clinical and Research Reports
Introduction ROS1 fusions are oncogenic drivers in 1% to 3% of NSCLCs. The activity of immune checkpoint inhibitor (ICI) monotherapy or in combination with chemotherapy (chemotherapy with ICI [chemo-ICI]) in these tumors and their immunophenotype hav
Publikováno v:
Journal of Case Reports and Images in Oncology. 7:1-1
Introduction: Tumor lysis syndrome (TLS) and hemophagocytic lymphohistiocytosis (HLH) are two medical emergencies associated with malignancy and treatment thereof. More commonly they are associated with treatment of fast growing and highly chemothera
Publikováno v:
Cancer Research. 81:1375-1375
Pemetrexed, a multi-targeted antifolate chemotherapy agent, has been used both as a single agent chemotherapy as well as in combination given its favorable side effect profile, and has been the only effective continuation maintenance chemotherapy reg
Autor:
Paul A. Bunn, Junxiao Hu, Jose Maria Pacheco, William T. Purcell, Yunan Nie, Erin L. Schenk, D. Ross Camidge, Tejas Patil
Publikováno v:
Journal of Clinical Oncology. 39:e21205-e21205
e21205 Background: Use of maintenance pemetrexed with pembrolizumab is the standard of care among patients with metastatic nonsquamous NSCLC without EGFR or ALK alterations treated with the KEYNOTE-189 regimen. Whether the addition of pembrolizumab t
Autor:
Noura J. Choudhury, Jaime Laurel Schneider, Tejas Patil, Viola Weijia Zhu, Debra A. Goldman, Soo-Ryum Yang, Christina Falcon, Andrew Do, Yunan Nie, Andrew J. Plodkowski, Jamie E. Chaft, Subba Digumarthy, Natasha Rekhtman, Maria E. Arcila, Alexia Iasonos, Sai-Hong Ignatius Ou, Jessica Jiyeong Lin, Alexander E. Drilon
Publikováno v:
Journal of Clinical Oncology. 39:9049-9049
9049 Background: ROS1 fusions are oncogenic drivers in various cancers types, including 1-3% of non-small cell lung cancers (NSCLCs). Immunotherapy approvals for NSCLC include ROS1-rearranged carcinomas, but the activity of immune checkpoint inhibiti